For decades, PDRN has relied on extraction from salmon reproductive cells. This traditional pathway is inherently constrained by fluctuations in fish supply, random DNA sequences, and challenges in purity control—making long-term consistency, scalability, and regulatory compliance difficult to guarantee.
Our Recombinant PDRN was developed to overcome these structural limitations through advanced bioengineering.
Free from animal sources, built on controlled biosynthesis
Using E. coli DH5α as a biological production platform, specific PDRN sequences are introduced via recombinant vectors and efficiently replicated through microbial fermentation.
This approach eliminates dependence on fish-derived materials, addressing supply instability and animal-origin safety concerns at the source, while aligning with the most stringent regulatory standards in the EU, the U.S., and global markets.
At the same time, the product remains DNA-based and naturally biosynthesized, making it a vegan, non-animal, yet biologically authentic alternative to traditional salmon-derived PDRN.
Precisely designed sequences, not random extraction
Unlike conventional PDRN obtained through non-selective extraction, recombinant technology enables full control over DNA sequence and fragment length.
Short-chain sequences can be designed for anti-inflammatory applications
Medium-to-long-chain sequences can be tailored to support collagen regeneration and skin repair
This transition—from random extraction to targeted biosynthesis—opens new possibilities for function-driven development and customized formulations.
Industrial-grade scalability and reproducibility
By integrating optimized heat-shock transformation and high-efficiency competent cell preparation, plasmid uptake and production yield are significantly improved.
Combined with multi-step physical shearing and ordered chromatographic purification, the process consistently achieves biomedical-grade purity (≥99.5%).
Standardized fermentation parameters further ensure smooth scale-up from pilot production to commercial manufacturing.
Efficacy validated by preclinical data
Preclinical studies demonstrate that recombinant PDRN delivers superior stimulation of human Type I collagen synthesis compared to conventional salmon-derived PDRN and DNA–metal complexes.
These results support its application in skin repair and anti-aging, offering a data-traceable, mechanism-driven ingredient solution.
Recombinant PDRN is more than a substitute—it is a technological upgrade.
By combining precise sequence design with controlled biosynthesis, recombinant technology maximizes PDRN bioactivity while providing a stable, vegan, and natural alternative to animal-derived PDRN—setting a new benchmark for next-generation skin regeneration ingredients.
Post time: Dec-31-2025